Coya Therapeutics Establishes $30M At-The-Market (ATM) Equity Offering Program

summarizeSummary

Coya Therapeutics has entered into an agreement to establish a new $30 million At-The-Market (ATM) equity offering program, providing capital for clinical development but posing significant potential dilution.

check_boxKey Events

• Establishes $30M ATM Offering

  Coya Therapeutics entered into a Sales Agreement with Leerink Partners LLC to sell up to $30 million of common stock through an At-The-Market (ATM) equity offering. This follows the 424B5 prospectus supplement filed concurrently on May 12, 2026, which launched the program.

• Significant Potential Dilution

  The $30 million offering represents a substantial potential dilution for existing shareholders, equivalent to approximately 30.6% of the company's current market capitalization if fully utilized.

• Funds Clinical Development

  The proceeds from the offering are intended to fund ongoing clinical development, which is critical for a life sciences company, especially following the recent FDA Fast Track Designation for its ALS drug candidate, COYA 302.

auto_awesomeAnalysis

This 8-K formalizes the establishment of an At-The-Market (ATM) equity offering program, allowing Coya Therapeutics to sell up to $30 million of common stock over time. While highly dilutive for existing shareholders, this program is crucial for a life sciences company to fund ongoing clinical development, particularly following the recent FDA Fast Track Designation for COYA 302. This capital raise extends the company's financial runway, supporting its pipeline.